At the Longevity Summit Dublin 2024, Alexandru-Ioan Voda and Alexandru Bacita, co-founders of The Cat Health Company, presented their work on developing longevity treatments for cats. They highlighted the faster regulatory process in veterinary markets compared to human drug development and shared their passion for improving the lives of cats, driven by personal and scientific interest. The team also introduced their AI-driven drug development pipeline and discussed their collaborations to advance feline healthcare, emphasizing the value of cross-industry partnerships in the longevity space.

Key Points:

• Focus on Veterinary Market for Longevity Drugs: Alexandru-Ioan Voda and Alexandru Bacita discuss their company's focus on developing drugs for cats, emphasizing the faster timeline of veterinary drug development (2-5 years) compared to human drugs (10-20 years).
• Cats as Ideal Models for Clinical Research: The speakers explain that cats are more suitable for research than dogs due to their smaller, more uniform size, making drug standardization and trial economics more efficient.
• Targeting Aging Mechanisms for Cats: Their company focuses on identifying targets for age-related diseases using AI and open-source tools. They believe single targets are not enough; instead, they aim to combine multiple pathways for better outcomes.
• Significant Collaboration in Longevity Research: The company has partnered with several notable organizations and researchers in the longevity field, including collaborations with Epitracker (a Florida-based company) and connections with major pharmaceutical companies.
• User-Friendly Drug Administration Solutions: They addressed concerns about patient compliance in cats, discussing practical methods like pill feeders and potential innovations such as cat-friendly formulations.